Every Form 4 that Annexon, Inc. (ANNX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANNX filings page.
Annexon, Inc. reported that director Mark S. Blumenkranz received a grant of 175,000 stock options on August 10, 2026. The options have an exercise price of $5.39 per share and expire on August 10, 2036. According to the vesting terms, 1/36 of the shares vest monthly starting from August 10, 2026, so all 175,000 underlying common shares are scheduled to be fully vested and exercisable on the third anniversary of that date, subject to his continuous service as a director.
Annexon, Inc. director William D. Waddill received a grant of stock options covering 65,000 shares of common stock at an exercise price of 4.70 per share. These options vest in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, as long as he continues serving as a director, and expire on June 11, 2036. Following this grant, he holds 65,000 options, reflecting routine equity-based director compensation rather than an open-market trade.
Annexon, Inc. director Muneer A. Satter received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting after that date, contingent on his continued board service.
Annexon, Inc. director William A. Jones Jr. received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 11, 2036.
The underlying shares vest and become exercisable in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, subject to his continuous service as a director until vesting.
Annexon, Inc. director Bettina M. Cockroft received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $4.7000 per share and expire on June 11, 2036.
According to the terms, all 65,000 underlying shares vest and become exercisable as to 100% of the total on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, subject to her continuous service as a director until the vesting date.
Annexon, Inc. director Jung Choi received a grant of stock options covering 65,000 shares of common stock at an exercise price of $4.70 per share. These options vest in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, subject to continued board service, and expire on June 11, 2036. Following this award, Choi holds stock options for 65,000 underlying shares directly.
Annexon director William H. Carson received a grant of stock options covering 65,000 shares of Annexon common stock, with an exercise price of $4.70 per share. These options were awarded as compensation rather than bought in the open market.
The options vest and become fully exercisable as to 100% of the shares on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, as long as he continues serving as a director through vesting. The options expire on June 11, 2036, and following this grant he holds derivative rights over 65,000 shares.
Annexon, Inc. executive Ted Yednock exercised stock options to acquire additional common shares. On June 11, 2026, he exercised options for 30,646 shares of Annexon common stock at an exercise price of $1.8501 per share. After the transaction, he directly owned 184,807 common shares. The exercised options were fully vested and exercisable, and this filing shows a routine conversion of derivative awards into stock rather than an open-market purchase or sale.
Annexon, Inc. director Muneer A. Satter, through an affiliated investment entity, reported a large open-market purchase of the company’s common stock. On May 28, 2026, Alerce Medical Technology Partners, L.P. bought 613,497 shares at a price of $5.41 per share, with Satter having sole voting and dispositive power over these shares.
After this transaction, entities associated with Satter are shown as holding 10,342,134 shares in total, including 240,000 shares in the Muneer A. Satter Revocable Trust and additional shares in various trusts and partnerships. Satter disclaims beneficial ownership of many of these indirect holdings except to the extent of his pecuniary interest.
Annexon, Inc. director William H. Carson bought 8,000 shares of common stock in an open-market transaction at $5.78 per share. After this purchase, he directly holds 78,405 shares of Annexon stock. The filing notes the transaction was made under his pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.
Annexon, Inc. director William H. Carson reported buying additional company stock. On April 10, 2026, he made an open-market purchase of 8,000 shares of common stock at $6.20 per share, bringing his direct holdings to 70,405 shares of Annexon common stock.
The filing notes that this transaction was executed under Carson’s Rule 10b5-1 trading plan, adopted on December 8, 2025, indicating the trade was pre-scheduled rather than a discretionary market-timing decision.
Annexon, Inc. director William H. Carson reported an open-market purchase of 8,000 shares of Common Stock at $5.67 per share. Following this transaction, he directly owns 62,405 shares. The filing notes the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.
Annexon, Inc.’s chief medical officer, Jamie Dananberg, reported an open-market sale of 5,820 shares of common stock. The shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this tax-related sale, Dananberg still holds 123,582 Annexon common shares directly.
Annexon, Inc. executive Michael Overdorf, EVP & Chief Business Officer, reported an open-market sale of 4,339 shares of common stock at a weighted average price of $5.42 per share. The filing states the shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this transaction, Overdorf beneficially owns 182,625 shares of Annexon common stock directly.
Annexon, Inc. executive vice president and chief innovation officer Ted Yednock reported an open-market sale of 5,566 shares of common stock at a weighted average price of $5.42 per share on March 2, 2026. The sale was made to cover tax withholding obligations from vesting RSUs, leaving him with 154,161 directly owned shares.
Annexon, Inc. executive vice president and chief scientific officer Dean Richard Artis sold 5,894 shares of common stock on March 2, 2026 in an open-market transaction to cover tax withholding obligations from vested restricted stock units. The weighted average sale price was $5.43 per share, and he held 180,093 shares afterward.
Annexon, Inc. Executive Vice President and Chief Financial Officer Jennifer Lew reported an open-market sale of 5,565 shares of common stock at a weighted average price of $5.42 per share. The shares were sold on March 2, 2026 to cover tax withholding obligations tied to vesting restricted stock units. After this tax-related sale, she held 170,700 shares of Annexon common stock directly.
Love Douglas reported acquisition or exercise transactions in this Form 4 filing.
Annexon, Inc. director and President & CEO Douglas Love reported receiving a grant of stock options covering 1,250,000 shares of the company’s stock. These are derivative securities, reflecting an equity incentive award rather than an open-market share purchase or sale.
According to the vesting terms, 1/48th of the option shares vest on each monthly anniversary starting on February 19, 2026, so the award becomes fully vested and exercisable on the fourth anniversary of that date. Vesting depends on Mr. Love’s continuous service with Annexon on each vesting date.
Annexon, Inc. reported that its Chief Medical Officer, Jamie Dananberg, received new equity awards on February 19, 2026. The awards include a stock option covering 225,000 shares at an exercise price of $0.00 per share and a grant of 56,250 shares of common stock in the form of restricted stock units (RSUs).
According to the filing, 1/48 of the option shares vest monthly starting from February 19, 2026, becoming fully vested on the fourth anniversary, subject to continued service. For the RSUs, one-third vests each year on February 19, with the first third vesting on February 19, 2027, also conditioned on continuous service. Following these grants, Dananberg directly owns 129,402 shares of common stock.
Annexon, Inc. executive Michael Overdorf, EVP & Chief Business Officer, reported equity awards consisting of stock options and restricted stock units. He was granted 250,000 stock options at an exercise price of $0.00 per share, with 1/48th of the option vesting monthly from February 19, 2026 so that all options vest over four years, subject to continued service. He also received 62,500 RSUs, each convertible into one share of common stock, with 1/3 vesting each year on February 19 starting in 2027, also conditioned on continued service.
Annexon, Inc. reported that EVP & Chief Scientific Officer Dean Richard Artis acquired equity awards on February 19, 2026. He received a stock option for 250,000 shares at an exercise price of $0.00 per share and 62,500 restricted stock units. The RSUs vest one-third each year on February 19, beginning in 2027, while 1/48 of the option vests monthly from February 19, 2026, becoming fully vested on the fourth anniversary, subject to his continuous service.
Annexon, Inc. reported that EVP & Chief Innovation Officer Ted Yednock acquired new equity awards. He received a stock option for 250,000 shares of common stock at an exercise price of $0.00 per share, vesting in equal monthly installments over four years starting on February 19, 2026.
He also received 62,500 restricted stock units, each RSU converting into one share of common stock upon vesting. One-third of these RSUs vest annually on February 19 of each year, with the first one-third vesting on February 19, 2027, subject to his continued service with the company.
Annexon, Inc. reported that EVP and Chief Financial Officer Jennifer Lew received equity awards on February 19, 2026. She was granted a stock option for 250,000 shares of common stock at an exercise price of $0.00 per share, vesting in equal monthly installments over four years starting from February 19, 2026. She also received 62,500 shares of common stock in the form of restricted stock units, each RSU representing one share upon vesting. One-third of these RSUs vest on February 19 of each year, with the first third vesting on February 19, 2027, subject to her continued service with the company.
Annexon, Inc. chief medical officer Jamie Dananberg reported an open-market sale of 5,290 shares of common stock at a weighted average price of $5.10 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related sale, Dananberg directly holds 73,152 Annexon shares.
Annexon, Inc. Executive Vice President and Chief Financial Officer Jennifer Lew reported an open-market sale of 7,851 shares of common stock at a weighted average price of $5.11 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units. After this transaction, she directly holds 113,765 shares of Annexon common stock.
Annexon, Inc. executive reports tax-related stock sale
Annexon, Inc. executive Dean Richard Artis, EVP & Chief Scientific Officer, reported an open-market sale of 5,290 shares of common stock at a weighted average price of $5.10 per share. According to the filing, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.
After this transaction, Artis beneficially owns 123,487 shares of Annexon common stock directly. The sale was executed in multiple trades within a price range of $4.925 to $5.155 per share.
Annexon, Inc. executive Ted Yednock reported an open-market sale of 7,857 shares of common stock on February 18, 2026, at a weighted average price of $5.11 per share. The filing notes the shares were sold to cover tax withholding obligations tied to vesting restricted stock units.
After this transaction, Yednock directly owned 97,227 Annexon shares. The sale was executed in multiple trades at prices ranging from $4.925 to $5.17, with the reported price reflecting the weighted average across those trades.
Annexon, Inc. executive Michael Overdorf, EVP & Chief Business Officer, reported an open-market sale of 6,225 shares of common stock at a weighted average price of $5.10 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units, and he held 124,464 shares afterward.
Annexon, Inc. director reports open-market stock purchase under a Rule 10b5-1 plan. On 12/01/2025, the reporting person bought 4,115 shares of Annexon common stock in a transaction coded as a purchase. The weighted average purchase price was $4.47 per share, with individual trades executed between $4.43 and $4.50.
After this transaction, the director beneficially owned 50,290 shares held directly. The filing notes that the trades were made pursuant to the director’s Rule 10b5-1 trading plan adopted on March 17, 2025, and the director has agreed to provide detailed trade information within the reported price range upon request.
Annexon, Inc. (ANNX) reported insider share purchases by director Muneer A. Satter through affiliated entities. On November 20, 2025, Alerce Medical Technology Partners, L.P. bought 400,000 shares of common stock at a weighted average price of $4.48. On November 21, 2025, Alerce Medical purchased an additional 422,613 shares at a weighted average price of $4.28. After these transactions, Satter is reported as beneficially owning 9,728,637 shares, held indirectly through a revocable trust, other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.
Annexon, Inc. (ANNX) director reports sizable insider stock purchases. Over three consecutive days in November 2025, the reporting person, through Alerce Medical Technology Partners, L.P., bought 500,000 Annexon common shares on each of 11/17, 11/18, and 11/19.
The weighted average purchase prices were reported as $2.99, $3.18, and $3.94 for each respective day, with trades executed within stated price ranges. After these transactions, the reporting person beneficially owned 8,906,024 shares indirectly, including shares held in a revocable trust, various other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, subject to stated pecuniary interests.
Annexon (ANNX) filed a Form 4 reporting an insider purchase by a director. On 10/30/2025, the director bought 4,115 shares of common stock at a $3.17 weighted average price, with individual trades executed between $3.15 and $3.20. The transaction was made under a Rule 10b5-1 trading plan adopted on March 17, 2025. Following the trade, the director beneficially owns 46,175 shares, held directly.
William H. Carson, a director of Annexon, Inc. (ANNX), purchased 4,115 shares of the company’s common stock on 09/30/2025 at a weighted average price of $3.05 per share under a Rule 10b5-1 trading plan adopted on March 17, 2025. After the reported purchase, the filing shows the reporting person beneficially owned 42,060 shares. The filing states the trades executed at prices ranging from $3.035 to $3.08, and the reporting person offers to provide details of the per-trade quantities on request. The transaction was reported on a Form 4 as required for Section 16 reporting.